Comparative Pharmacology
Head-to-head clinical analysis: ACTOPLUS MET versus PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTOPLUS MET versus PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE.
ACTOPLUS MET vs PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Actoplus Met combines pioglitazone, a thiazolidinedione that improves insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPARγ), and metformin, a biguanide that decreases hepatic glucose production and improves peripheral glucose uptake.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in peripheral tissues and reducing hepatic gluconeogenesis. Glimepiride is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
ACTOPLUS MET (pioglitazone/metformin) is available as tablets of 15 mg/500 mg, 15 mg/850 mg, and 15 mg/1000 mg. The usual starting dose is 15 mg/500 mg twice daily or 15 mg/850 mg once daily, gradually titrated based on glycemic response and tolerability. Maximum recommended dose is 45 mg pioglitazone and 2000 mg metformin per day.
Oral, 1 tablet containing pioglitazone 15-30 mg and glimepiride 1-4 mg once daily with the first main meal; maximum daily doses: pioglitazone 45 mg, glimepiride 8 mg.
None Documented
None Documented
Pioglitazone: terminal half-life 3–7 hours (parent drug) for elimination, with active metabolites prolonging clinical effects up to 24 hours. Metformin: 6.2 hours (plasma), prolonged to 17.6 hours in renal impairment (e.g., CrCl <60 mL/min).
Pioglitazone: 3–7 hours (parent), 16–24 hours (active metabolites); clinically, once-daily dosing due to metabolite activity. Glimepiride: 5–9 hours (terminal), with prolonged effect in renal impairment.
Pioglitazone: predominantly hepatic metabolism and biliary excretion of metabolites, with 15–30% recovered in urine (mostly metabolites) and the remainder in feces. Metformin: 90% excreted unchanged in urine via glomerular filtration and tubular secretion, with <10% in feces.
Pioglitazone: 30% renal (as metabolites, <2% unchanged); 70% fecal/biliary. Glimepiride: 60% renal (metabolites), 40% fecal/biliary.
Category C
Category A/B
Thiazolidinedione/Biguanide Combination
Thiazolidinedione